Moteur de recherche d’entreprises européennes
Financement de l’UE (5 899 250 €) : Réparation des lésions tissulaires et organiques dans la maladie chronique réfractaire du greffon contre l’hôte après une greffe de cellules souches … Hor01/01/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Réparation des lésions tissulaires et organiques dans la maladie chronique réfractaire du greffon contre l’hôte après une greffe de cellules souches hématopoïétiques par perfusion de lymphocytes T régulateurs allogéniques purifiés
Our proposal encompasses parallel clinical trials addressing the feasibility and the effectiveness of donor-derived regulatory T cells (Treg) as a therapeutic agent in the treatment and prevention of tissue and organ damage resulting from graft versus host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). We propose a collaborative clinical study in which Treg therapy for GHVD is the common dominator. However, by bringing together several clinical centers with expertise in this area, we are also having the opportunity to simultaneously address other issues that would not otherwise be addressable by each clinical center on its own. Firstly, by using different Treg preparation strategies, we will be able to determine whether ex vivo isolated Treg are sufficient or whether in vitro expansion and subsequently higher dosages are required. Secondly, we will investigate if sole Treg infusion is effective or if rather co-administration of therapeutic agents that are likely to induce Treg survival and expansion in vivo (rapamycin; IL-2) is required for a successful response to Treg therapy. The studies on GVHD treatment outcome will be pursued together with a detailed analysis of immune monitoring, comprising T cell receptor clonotype tracking and tissue regeneration markers, in order to further understand the mechanisms underlying the therapeutic and regenerative potential of Treg cells. Our consortium has developed a concerted approach to the topic of Treg therapy in GVHD. This is a unique opportunity to determine the validity of this cellular immunotherapy approach in GVHD prevention and treatment, with potential for a significant impact on patient quality of life, survival rate and ultimately on the quality of health care provided.
| ALACRIS THERANOSTICS GmbH | 277 500 € |
| GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM mbH & Co. KG | 88 919 € |
| Instituto de Medicina Molecular Joao Lobo Antunes | 1 886 979 € |
| Irccs Azienda Ospedaliero- Universitaria Di Bologna | 627 453 € |
| KLINIKUM DER UNIVERSITAET REGENSBURG | 1 423 824 € |
| MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN e. V. | 741 335 € |
| Servicio Andaluz de Salud | 365 420 € |
| The University of Liverpool | 246 078 € |
| Universite de Liege | 241 743 € |
https://cordis.europa.eu/project/id/643776
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.